Following the high-profile failure of its lead product in February, Celsus Therapeutics is merging with Volution Immuno Pharmaceuticals in an all-stock transaction that will allow the company the ability to access cash and continue funding its other development programs.
Celsus becomes Akari after trial failure
More from Archive
More from Scrip
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.
• By
Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.